128 results about "Fibronectin" patented technology

The invention belongs to the technical field of cosmetics, and discloses a wrinkle-removing and anti-aging composition containing recombinant collagen as well as a preparation method and application of the wrinkle-removing and anti-aging composition. The composition is prepared from the following components: 20.4 to 35.6 percent of glycerol, 1.1 to 3.5 percent of 1, 2-hexanediol, 8.2 to 15.4 percent of apple fruit cell culture extract, 1.6 to 3.2 percent of inositol, 0.2 to 1.0 percent of elastin, 0.1 to 1.7 percent of hydroxyproline, 0.1 to 1.0 percent of sodium polyglutamate, 0.1 to 1.0 percent of sodium hyaluronate, 0.01 to 0.1 percent of acetyl hexapeptide-8, 0.01 to 0.1 percent of fibronectin, 1.72 to 3.21 percent of soluble collagen and the balance of deionized water. The amino acid sequence of the soluble collagen is as shown in SEQ ID NO. 1. The skin care product prepared by adding the anti-wrinkle and anti-aging composition is good in safety and has the effects of resisting wrinkles, improving skin elasticity and resisting aging.

The invention relates to a plasma biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the plasma biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), fibronectin 1 (FN1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and an Aly / REF output factor (ALYREF). The plasma biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.

The invention provides an EP300 detection preparation and application of EP300 in a product for treating rheumatoid arthritis, and relates to the technical field of biological medicines. The rheumatoid arthritis symptom is relieved by inhibiting EP300 gene expression, after EP300 is knocked down in human THP-1-derived macrophages, H3K18 lactylation expression is reduced, and after EP300 is knocked down in human THP-1-derived macrophages, EP300 and human synovial cells are co-cultured, so that the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, the human THP-1-derived macrophages are subjected to H3K18 lactylation expression is reduced, and the human THP-1-derived macrophages are obtained. Through the crosstalk effect between human THP-1-derived macrophages and human synovial cells, the expression of inflammatory markers MMP3 and Fibronectin in the synovial cells can be remarkably inhibited, compared with a model group, the proliferation capacity of the synovial cells is weakened, a potential treatment target is provided for treating rheumatoid arthritis, and the application has the advantages that the application is easy to popularize and use, and the application has a wide application prospect. The pathogenesis of rheumatoid arthritis is perfected, and hope is brought to research and development of novel biomarkers for early diagnosis, targeted therapy and prognosis evaluation of rheumatoid arthritis.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

Provided herein are methods of preparing modified fibronectin proteins. Also provided herein are methods of preparing such modified fibronectin proteins and their use in connection with purifying components of interest. Also provided herein are methods of preventing filter fouling using cell lines engineered to express the modified fibronectin proteins described herein.

The invention relates to the technical field of artificial dermis, in particular to a preparation method and application of artificial dermis based on bionic acellular matrix. The artificial dermis comprises a bionic acellular matrix component A and an auxiliary material component B, wherein the component A comprises type I collagen, type VI collagen, elastin, fibronectin, laminin, mother cell protein and glucan; the component B comprises antibacterial peptide, antibiotics and a high-molecular polymer material; the mass ratio of the component A to the component B is (4-6): (1-4). The preparation method comprises the following steps: respectively preparing procedure mother liquor of the component A and the component B, preparing hydrogel with a double-layer gradient structure through step-by-step crosslinking, and then carrying out freeze drying and sterilization treatment. The artificial dermis disclosed by the invention has good biocompatibility and antibacterial property, can effectively promote wound healing, is suitable for repairing acute and chronic wounds of four limbs, faces and trunk parts, and is particularly suitable for repairing complex wounds with exposed bones, tendons, nerves and blood vessels.

This invention provides a liquid crystal biomimetic water-locking and oxygen-permeable skincare composition, its preparation method, and its application, belonging to the field of cosmetic technology. It comprises the following components by weight percentage: 20-40% glycerin, 5-10% hydrogenated lecithin, 5-10% phytosterols, 0.1-0.5% sodium stearoyl glutamate, 0.01-0.05% sodium methylstearoyl taurate, 0.1-1% ceramide NP, 1-10% caprylic / capric triglyceride, 1-10% squalane, 0.1-1% tocopheryl acetate, 0.01-0.3% sodium DNA, 0.001-0.1% fibronectin, 0.001-0.1% soluble collagen, and the balance being water. The liquid crystal biomimetic water-locking and oxygen-permeable skincare composition provided by this invention can better form a breathable protective film on the skin surface, reduce skin moisture loss, and help repair damaged skin barriers, thereby achieving the effect of water-locking and oxygen-permeable skincare.

The invention belongs to the technical field of cosmetics, and discloses a composition with tightening, moisturizing and repairing effects as well as a preparation method and application thereof. The composition is prepared from the following components in parts by mass: 1 to 30 parts of elastin, 1 to 30 parts of fibronectin, 1 to 40 parts of milk protein and 1 to 35 parts of agilawood extract. The composition disclosed by the invention is mild and non-irritant, is good in formula stability, and has multiple skin care effects of tightening, moisturizing and repairing, so that the composition has a wide application prospect in the development of cosmetics.

The invention provides a culture medium for NK cell culture and a preparation method of NK cells. The culture medium comprises a coating solution, an activation culture medium and a proliferation culture medium, the coating solution comprises an antibody, recombinant human fibronectin and a buffer solution; the activation culture medium comprises a first cell factor, a glycogen synthase kinase inhibitor and an NK basal culture medium; the proliferation culture medium comprises a second cell factor and an NK basal culture medium. The problem that in the prior art, prepared NK cells are poor in quality can be solved, and the method is suitable for the field of cell culture.

The invention discloses a serum protein marker combination for detecting cerebral microhemorrhage, and belongs to the field of biological medicine detection.The serum protein marker combination comprises four serum proteins including matrix metalloproteinase 3, fibronectin-like extracellular matrix protein 1 containing epidermal growth factors, a metalloproteinase inhibiting factor 1 and uromodulin; through efficient and accurate serum protein marker combination, the defects that brain function magnetic resonance SWI examination is high in cost and long in time consumption, operation depends on high-level imaging physicians and the like are overcome, an innovative tool is provided for rapid, accurate and non-invasive screening and auxiliary diagnosis of cerebral microhemorrhage, and wide clinical application prospects are achieved.

The invention belongs to the technical field of protein engineering, and discloses a humanized collagen XVII type polypeptide as well as a preparation method and application thereof. The amino acid sequence of the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.1, and the polynucleotide sequence for coding the humanized collagen XVII type polypeptide is as shown in SEQ ID NO.2. The invention also provides application of the polypeptide in preparation of a protein product with functions of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin. The application proves that the humanized collagen XVII type polypeptide can promote proliferation of hair papilla cells, keratinocytes and fibroblasts and promote up-regulation of expression of beta-Catenin signal channel protein closely related to hair growth in the hair papilla cells; the up-regulation expression of fibroblast type III collagen, type IV collagen, type VII collagen, fibronectin and elastin is promoted, so that the polypeptide is proved to have the effects of preventing hair loss and growing hair and / or repairing, resisting wrinkles and tightening skin.

The invention provides a compound fermentation polypeptide composition with whitening, anti-aging, moisturizing and repairing functions and application thereof, and belongs to the technical field of skin care products. The composite fermentation polypeptide composition comprises the following components: a micrococcus lysate, crithmum maritimum callus culture filtrate, a bifidobacterium fermentation product filtrate, a galactose yeast-like bacterium fermentation product filtrate, a tuber melanosporum extract, a peony root extract, acetyl hexapeptide-8, nonapeptide-1, hexapeptide-9, tetrahydromethylpyrimidine carboxylic acid, fibronectin and the like. The composite fermented polypeptide composition not only realizes multi-dimensional mildness and aging resistance, but also has the characteristics of brightening skin, enhancing skin barrier and the like, and is suitable for the field of skin care products.

The invention provides a composition and application thereof in promoting wound healing and reducing scar formation. The composition comprises 10 < 4 >-10 < 9 > particles / mL of exosomes and 5-1000 [mu] g / mL of fibronectin. Through collaborative design of the exosome and fibronectin, multi-mode regulation of promoting repair, controlling inflammation, regulating matrix and reducing scars on wound healing is realized, and the exosome has the advantages of comprehensive action mechanism, stable treatment effect and wide application range; the obvious application value and clinical transformation potential are realized in the fields of chronic wound repair, scar prevention and treatment and skin regeneration.

The present invention provides a method for testing a possibility of liver cancer development. A method for testing a possibility of liver cancer development includes step (1) of detecting at least one target molecule selected from the group consisting of Fibulin-3, GPNM3, Fibulin-3 mRNA, and GPNMB mRNA in a biological sample collected from a subject.

The present invention provides anti-human LILRB4 monoclonal antibodies or fragments thereof, immune checkpoint inhibitors, therapeutic agents for immune checkpoint-related diseases, and methods for measuring human LILRB4.SOLUTION: Anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof that specifically bind to a human immunosuppressive receptor LILRB4 and inhibit binding between fibronectin and the human immunosuppressive receptor LILRB4, immune checkpoint inhibitors containing the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof as active ingredients, therapeutic agents for immune checkpoint-related diseases, and methods for measuring a human immunosuppressive receptor LILRB4 in a biological sample using the anti-human immunosuppressive receptor LILRB4 monoclonal antibodies or fragments thereof.SELECTED DRAWING: None

The application discloses application of a GPR146 inhibitor in preparation of a drug for treating wet age-related macular degeneration. The application finds that GPR146 is significantly up-regulated in expression in a mouse model of laser-induced CNV and a mouse model of subretinal fibrosis. In mice, shRNA is used to knock down GPR146, thereby significantly inhibiting CNV, subretinal fibrosis and inflammation. In an in-vitro experiment, siRNA targeting GPR146 can inhibit the in-vitro neovascular function of endothelial cells, such as proliferation, migration and tube formation, and reduce immune cell adhesion and transendothelial cell migration. In addition, targeting GPR146 can also inhibit the expression of TGF-beta, Fibronectin (FN), alpha-SMA, Col1A, MMP9 and other fibrosis-promoting molecules by endothelial cells. Meanwhile, targeting GPR146 can also inhibit the proliferation and migration of smooth muscle cells and reduce the expression of the above fibrosis-promoting molecules. The above results all show that targeting GPR146 can significantly inhibit CNV formation, inflammation and subretinal fibrosis, and has good therapeutic effect.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The invention relates to a fibronectin functionalized drug-loaded phosphorus-containing crown macromolecular nano-micelle as well as a preparation method and application thereof. The drug-loaded phosphorus-containing crown macromolecular nano-micelle comprises phosphorus-containing crown macromolecules at the tail end of a hydroxyl group, docosahexaenoic acid and fibronectin, the phosphorus-containing crown macromolecule at the terminal of the hydroxyl group encapsulates docosahexaenoic acid in a hydrophobic cavity of the nano-micelle through self-assembly, and the docosahexaenoic acid is further compounded with fibronectin to form the multifunctional drug-loading phosphorus-containing crown macromolecule nano-micelle. The multifunctional nano-micelle provided by the invention can penetrate through a blood brain barrier and cooperatively regulate and control microglial cells and nerve cells at an injured part, can realize combined treatment of oxidative stress relief, immune regulation and control, nerve protection and vascular regeneration of ischemic cerebral apoplexy, and has a good clinical transformation prospect and application value.

The present application relates to a composition with whitening effect and its preparation method and application, the composition with whitening effect includes: ascorbic acid polypeptide, dimethyl methoxy benzodioxole, fibronectin, sea beet extract and methoxy cinnamic acid ethyl hexyl ester. The application creatively finds that the composition of ascorbic acid polypeptide, dimethyl methoxy benzodioxole, fibronectin, sea beet extract and methoxy cinnamic acid ethyl hexyl ester can effectively inhibit the multiple pathways of melanin production, so as to achieve the effect of more excellent skin whitening, and the five components have certain synergistic effect on the above effect, and are very suitable for whitening cosmetics, mild and non-irritating.

The invention discloses a fibroblast composite bone filling preparation as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the following steps: specifically culturing fibroblasts by using Yoda1 and matrix I-type collagen, and activating the osteogenic differentiation capability of the fibroblasts; resuspending the finished product fibroblasts capable of activating the osteogenic differentiation capacity in a solution containing ginsenoside, tacrolimus and fibronectin to obtain a mixed solution; and finally, mixing the mixed solution with the bone filler to obtain the fibroblast composite bone filling preparation capable of promoting repair. The preparation can provide fibrosis support and promote vertebra fusion, does not cause inflammatory reaction, and has a large-scale application prospect.

The invention relates to the technical field of medicines, in particular to a composition for promoting cervical erosion and skin wound healing and repairing scars. The composition is prepared from the following raw materials in percentage by mass: 3% of propylene glycol, 0.56% of carbomer, 2.5% of fructo-oligosaccharide, 3% of an oat beta-glucan solution, 0.1% of tetrahydropiperine, 0.5% of triethanolamine, 3.0% of a saccharomycetes lysate extracting solution, 4% of a physalis alkekengi extracting solution, 1.0% of a composite plant fungicide, 1.0%-4.0% of a fibronectin solution and 1.0%-2.0% of a starfish coelomic fluid extract. And the balance of water. According to the invention, the physalis alkekengi extract, the composite plant fungicide and other components are mutually cooperated and matched to achieve the best anti-inflammatory and antibacterial effects; according to the invention, fibronectin is migrated, bonded and used for repairing an injured wound surface, then the starfish coelomic fluid extract is used for promoting skin growth, and the fibronectin and the starfish coelomic fluid extract are mutually cooperated and matched, so that wound surface healing can be well promoted, no scar is left, and the scar can be well removed.

The invention provides a serum-free medium for maintaining dryness of mesenchymal stem cells as well as a preparation method and application of the serum-free medium, and belongs to the technical field of biological medicines. The serum-free culture medium comprises a basic culture medium and an exogenous additive component, the basic culture medium is a DMEM / F12 culture medium, and the exogenous additive components comprise bFGF, EGF, PDGF-BB, recombinant human fibronectin, laminin, insulin, transferrin, sodium selenate, beta-mercaptoethanol and ascorbic acid. The serum-free culture medium provided by the invention is a special culture medium for the mesenchymal stem cells, which is completely free of animal-derived components, is suitable for large-scale amplification of clinical-grade cell treatment products, is relatively low in preparation cost and high in stem differentiation capability, and can remarkably improve the proliferation efficiency of the cultured mesenchymal stem cells.